Multimodal Endoscopic Image Fusion for Assessing Infiltration in Superficial Esophageal Squamous Cell Carcinoma

Launched by CHANGHAI HOSPITAL · May 10, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to improve the detection of early-stage esophageal cancer and its precancerous conditions. Researchers are developing advanced systems that use artificial intelligence (AI) to help doctors better identify and understand how deeply the cancer has invaded the esophagus. By combining two techniques—endoscopic ultrasound (EUS) and magnifying endoscopy—this study aims to make the screening process quicker, easier to learn for medical staff, and more accurate than current methods. The ultimate goal is to find cancer earlier, which can lead to better treatment outcomes.

To participate in this trial, individuals must be 18 years or older and need specific endoscopic tests. However, people with advanced esophageal cancer, certain medical histories, or those unable to complete the required procedures might not be eligible. Participants can expect to undergo a series of tests using the new AI-assisted systems, which may help improve the accuracy of their diagnosis. It’s important to note that this study is not open for enrollment yet, but it represents an exciting step forward in the fight against esophageal cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients requiring magnifying endoscopy and endoscopic ultrasonography. Individuals of either sex, aged 18 years or older.
• Exclusion Criteria:
• • Inability to complete esophageal electronic endoscopy. Absence of biopsy or surgery, resulting in unobtainable pathological results. Patients who have undergone endoscopic lesion destruction or piecemeal resection, preventing the acquisition of an en bloc resection sample.
• • Patients with significant endoscopic, imaging, or pathological evidence of advanced esophageal cancer.
• • Patients presenting with marked esophageal stenosis or dilatation. Individuals with a history of other malignancies. Patients who have received neoadjuvant radiotherapy. Patients who declined to participate in the study and did not provide informed consent.